156 related articles for article (PubMed ID: 22190969)
1. Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Kobold S; Tams S; Luetkens T; Cao Y; Sezer O; Bartels BM; Reinhard H; Templin J; Bartels K; Hildebrandt Y; Lajmi N; Marx A; Haag F; Bokemeyer C; Kröger N; Atanackovic D
Clin Dev Immunol; 2011; 2011():302145. PubMed ID: 22190969
[TBL] [Abstract][Full Text] [Related]
2. Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.
Yousef S; Heise J; Lajmi N; Bartels K; Kröger N; Luetkens T; Atanackovic D
J Transl Med; 2015 Jun; 13():197. PubMed ID: 26088750
[TBL] [Abstract][Full Text] [Related]
3. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
Spisek R; Kukreja A; Chen LC; Matthews P; Mazumder A; Vesole D; Jagannath S; Zebroski HA; Simpson AJ; Ritter G; Durie B; Crowley J; Shaughnessy JD; Scanlan MJ; Gure AO; Barlogie B; Dhodapkar MV
J Exp Med; 2007 Apr; 204(4):831-40. PubMed ID: 17389240
[TBL] [Abstract][Full Text] [Related]
4. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
Atanackovic D; Arfsten J; Cao Y; Gnjatic S; Schnieders F; Bartels K; Schilling G; Faltz C; Wolschke C; Dierlamm J; Ritter G; Eiermann T; Hossfeld DK; Zander AR; Jungbluth AA; Old LJ; Bokemeyer C; Kröger N
Blood; 2007 Feb; 109(3):1103-12. PubMed ID: 17023585
[TBL] [Abstract][Full Text] [Related]
5. Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.
Bellucci R; Oertelt S; Gallagher M; Li S; Zorn E; Weller E; Porcheray F; Alyea EP; Soiffer RJ; Munshi NC; Gershwin ME; Ritz J
Blood; 2007 Mar; 109(5):2001-7. PubMed ID: 17068145
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
7. SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma.
Sun Y; Zhang R; Wang M; Zhang Y; Qi J; Li J
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2043-7. PubMed ID: 22832207
[TBL] [Abstract][Full Text] [Related]
8. Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
Tovar N; Fernández de Larrea C; Pedrosa F; Aróstegui JI; Cibeira MT; Rosiñol L; Elena M; Filella X; Yagüe J; Bladé J
Ann Hematol; 2014 Jan; 93(1):107-11. PubMed ID: 24218189
[TBL] [Abstract][Full Text] [Related]
9. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
Cao Y; Luetkens T; Kobold S; Hildebrandt Y; Gordic M; Lajmi N; Meyer S; Bartels K; Zander AR; Bokemeyer C; Kröger N; Atanackovic D
Exp Hematol; 2010 Oct; 38(10):860-7. PubMed ID: 20619313
[TBL] [Abstract][Full Text] [Related]
10. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
11. Presence of serum carbonic anhydrase autoantibodies in patients relapsed after autologous stem cell transplantation indicates an improved prognosis.
Lakota J; Skultety L; Dubrovcakova M; Altaner C
Neoplasma; 2008; 55(6):488-92. PubMed ID: 18999876
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
Bellucci R; Alyea EP; Chiaretti S; Wu CJ; Zorn E; Weller E; Wu B; Canning C; Schlossman R; Munshi NC; Anderson KC; Ritz J
Blood; 2005 May; 105(10):3945-50. PubMed ID: 15692072
[TBL] [Abstract][Full Text] [Related]
13. Identification of carbonic anhydrase I immunodominant epitopes recognized by specific autoantibodies which indicate an improved prognosis in patients with malignancy after autologous stem cell transplantation.
Skultety L; Jankovicova B; Svobodova Z; Mader P; Rezacova P; Dubrovcakova M; Lakota J; Bilkova Z
J Proteome Res; 2010 Oct; 9(10):5171-9. PubMed ID: 20681519
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Montefusco V; Spina F; Patriarca F; Offidani M; Bruno B; Montanari M; Mussetti A; Sperotto A; Scortechini I; Dodero A; Fanin R; Valagussa P; Corradini P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):424-8. PubMed ID: 23142330
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
Kobold S; Luetkens T; Bartels BM; Cao Y; Hildebrandt Y; Sezer O; Reinhard H; Templin J; Bartels K; Lajmi N; Haag F; Bokemeyer C; Kröger N; Atanackovic D
Clin Dev Immunol; 2012; 2012():134081. PubMed ID: 22481961
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
Holstein SA; Suman VJ; Owzar K; Santo K; Benson DM; Shea TC; Martin T; Silverman M; Isola L; Vij R; Cheson BD; Linker C; Anderson KC; Richardson PG; McCarthy PL
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1414-1424. PubMed ID: 32325171
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation for multiple myeloma.
Bensinger W
Hematol Oncol Clin North Am; 2014 Oct; 28(5):891-902. PubMed ID: 25212888
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.
Danylesko I; Shimoni A; Nagler A
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S330-48. PubMed ID: 24290219
[TBL] [Abstract][Full Text] [Related]
19. Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Fabre C; Koscielny S; Mohty M; Fegueux N; Blaise D; Maillard N; Tabrizi R; Michallet M; Socié G; Yakoub-Agha I; Garban F; Uzunov M; François S; Contentin N; Lapusan S; Bourhis JH
Haematologica; 2012 Apr; 97(4):482-90. PubMed ID: 22058218
[TBL] [Abstract][Full Text] [Related]
20. Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.
Ma SY; Lie AK; Au WY; Chim CS; Kwong YL; Liang R
Hong Kong Med J; 2004 Apr; 10(2):77-83. PubMed ID: 15075426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
